Goldman Sachs analysts reinstated coverage of Medtronic plc with a neutral rating and a price target of $84 [1].
The move comes as the Dublin-based medical technology company struggles to match the revenue growth of its larger MedTech competitors, including Johnson & Johnson, and Abbott.
Analysts said the company is facing a widening growth gap driven by competitive pressure and slower sales across its core product lines [1]. This reassessment of the stock's outlook suggests that Medtronic may struggle to regain its previous momentum without significant changes to its product trajectory.
Market performance has reflected these concerns. Medtronic shares have fallen about 11.5% [2] since the last earnings report, a trend that has seen the stock underperform the S&P 500 [2].
"Goldman Sachs reinstated coverage of Medtronic plc with a neutral rating and an $84 price target," Goldman Sachs analysts said [1].
The company is now approaching a critical financial milestone. Medtronic is scheduled to release its fiscal Q4 2026 earnings on June 3, 2024 [3]. This report will likely serve as a primary indicator of whether the company can narrow the gap with its rivals or if the current stagnation will persist.
Medtronic, which is listed on the New York Stock Exchange under the ticker MDT, maintains global operations from its headquarters in Ireland. The current neutral stance from Goldman Sachs reflects a cautious approach to the stock's valuation ahead of the upcoming earnings call.
“Medtronic shares have fallen about 11.5% since the last earnings report”
The neutral rating from a major financial institution like Goldman Sachs indicates a lack of confidence in Medtronic's short-term ability to outpace its peers. With a significant share price decline and a looming earnings report, the company is under pressure to demonstrate a viable strategy for recovering lost market share in the highly competitive MedTech sector.
